Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison.
about
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015Imago Mundi, Imago AD, Imago ADNIResting state functional connectivity in preclinical Alzheimer's diseaseNeuroimaging of dementia in 2013: what radiologists need to know.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Future Directions in Imaging Neurodegeneration.Everyday cognition scales are related to cognitive function in the early stage of probable Alzheimer's disease and FDG-PET findingsDiagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical settingStudying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometryAssociation between an Alzheimer's Disease-Related Index and APOE ε4 Gene DoseVolume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysisConstruction and comparative evaluation of different activity detection methods in brain FDG-PET.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsQuantitative Imaging Analysis of FDG PET/CT Imaging for Detection of Central Neurolymphomatosis in a Case of Recurrent Diffuse B-Cell LymphomaApolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging.Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.FDG-PET Contributions to the Pathophysiology of Memory Impairment.Automated identification of dementia using FDG-PET imaging.The emerging role of PET imaging in dementia.Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.Measurement of inter- and intra-observer variability in the routine clinical interpretation of brain 18-FDG PET-CT.A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia.Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.Early identification of MCI converting to AD: a FDG PET study.Brain Network Alterations in Alzheimer's Disease Identified by Early-Phase PIB-PET.Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer’s disease
P2860
Q26801654-B3AF2603-BABC-47F5-BAC9-0688465C02A9Q28650395-8B0E9EEF-84A2-4339-B811-67F460A28D64Q30531401-0B8C1787-F2F8-440D-B677-E46830C9BE88Q30654332-17A8BC89-D663-49E2-90E4-BC1C14A89958Q30971403-8D7D351E-FE0D-4C1E-BF28-BDD9A8859FCBQ31162702-4A5DC95E-643D-40AD-B878-78277F4D321BQ33687460-B429631C-D189-4954-828F-5972072A2B97Q33758587-C2CFBA30-BA1A-49F7-A0E3-275A3EEF8DDBQ34477727-8DA3BF28-FCAC-4A4E-9E4D-912DD9DDDB1EQ34615211-210C854A-3FE1-4C32-9911-87F310D5098DQ34806627-E5C5EB00-D5C6-496B-9671-E3BF55CCA2CBQ34988405-2F9F9213-C35B-45A7-8EB7-4FC6EE67C604Q35158547-447D23AC-F687-489D-8E21-9B80DC26E00EQ35964685-A73EC275-181F-403B-8090-2C2B0E1776C7Q36165011-04923F22-6B09-4D43-B696-FD01BD88AE7CQ36399589-C3093354-DEFD-49CE-88DE-BA4B82DAAEBBQ36510817-D2CD8EE7-69ED-4C30-9603-75F6B10DC01FQ36933700-3E0A50B4-A5C6-4827-8908-A18E52E05676Q37436607-EC432EF9-9121-44E1-A5E0-BB7146AB57C4Q38037156-E1A59F63-6625-45EA-B78C-EA0D597F5B4AQ38576278-FDCEA983-46D3-44D1-AFF2-4C452AEC47F7Q41966140-65E5768D-9979-4F1A-A773-62024CAA3050Q42701971-766768DF-3B5E-4FF6-8D6C-D4607F97EFAFQ45178246-AE26FA9B-1104-4033-98E2-757F53291E67Q47553874-C44C17CC-19D0-4BEF-8D73-BA0E0F2060A4Q48132965-C71CBFAB-9071-499C-A1AE-1483364718D3Q48449897-F301F6B3-E644-47C5-8C98-A0401016B514Q48704076-DAF9FC8C-069E-4744-B94C-47BA326FD3DBQ48715994-5ED0F000-26C7-46DD-8E58-340646FBFE01Q50479860-51CE8F3A-5710-4F20-B8CF-29233ADEEF93Q50553129-CC01A81C-0C56-4FE8-9D33-209BEFABB4A3Q55072841-94345B24-EF9B-4245-8556-F232BFAD71D0Q57741276-ADE5D7AD-5AD8-4349-9A9B-5823781FC4C2
P2860
Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@ast
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@en
type
label
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@ast
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@en
prefLabel
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@ast
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@en
P2093
P2860
P50
P1476
Summary metrics to assess Alzh ...... PET: head-to-head comparison.
@en
P2093
Anna Caroli
Cathleen Haense
Cindee M Madison
EADC-PET Consortium, NEST-DD, and Alzheimer's Disease Neuroimaging Initiative
Karl Herholz
Napatkamon Ayutyanont
Susan M Landau
William J Jagust
P2860
P304
P356
10.2967/JNUMED.111.094946
P407
P577
2012-02-17T00:00:00Z